Board of Directors
You are here
Joel is a Partner at TPG Capital and leads the firm’s investment program in the ANZ region as Head of Australia and New Zealand. Joel also currently sits on the Board of Inghams Group Limited and has served on the Boards of Accolade Wines, Gerard Lighting, Blue Star Print Group and Centric Wealth.
Before joining TPG, Joel was a Director at CHAMP Private Equity; where he was responsible for the company’s activities in the industrial, agricultural services and consumer markets. Prior to CHAMP, Joel was a Vice President at Dyno Nobel Limited, where he led acquisitions in China, Europe and North America; and held strategic and operational positions at Boral Limited in the United States. Joel is a Guest Lecturer on Private Equity at Melbourne Business School.
Dr. Fred Cohen
Fred Cohen is a Senior Advisor to TPG and was a Partner and co-founder of TPG Biotechnology. Fred has served on the Board of several biotech and pharmaceutical organizations including Biocryst (BCRX), CareDx (CDNA), Five Prime Therapeutics (FPRX), Genomic Health (GHDX), Progyny, Tandem Diabetes (TNDM), UroGen (URGN), Veracyte (VCYT) and is a co-founder of Sweetwater Spectrum, a non-profit autism support organization.
Fred has published over 200 peer reviewed articles, participated as a co-inventor on over 10 patents and has served as an editor or editorial board member of several international scientific journals. He is also a Fellow of the American College of Physicians, the American College of Medical Informatics and a Member of the National Academy of Medicine of the United States, The American Academy of Arts and Sciences, American Society for Clinical Investigation and the Association of American Physicians.
Scott is a Partner and Managing Director of TPG. Scott is Head of TPG’s Beijing office and leads investment opportunities for TPG Capital in Greater China. In addition to serving as Board Director of Novotech, Scott currently serves as Co‐Chairman of the Board and has served as interim Chief Operating Officer at Untied Family Healthcare, China’s largest private premium healthcare service. Scott has served or serves on the Board of Directors of leading Greater China CRO OPC, sports apparel company Li Ning, cosmetics packaging company HCP and Taiwan’s Taishin Bank.
Fiona Pak Poy
Fiona is a non-executive director at Novotech. Fiona also currently serves as a non-executive director for several companies including Isentia, MYOB and the Securities Industry Research Centre of South East Asia. She is a Committee Member of the Biomedical Translational Fund, part of the Australia government’s National Science and Innovation Agenda; and a Member of the Australian Securities Investment Commission (ASIC)’s Director Advisory Panel.
Fiona was previously a General Partner at venture capital fund Innovation Capital, a Councillor for Australian Private Equity and Venture Capital Association and on the board for Innovation Australia, an independent body established to assist with the administration of the Australian Government’s innovation programs. Fiona has worked as an executive, board member or investor with start-ups to ASX100 and Fortune 500 companies, both in Australia and the United States.
John joined Novotech in January 2014 to lead the development of Novotech’s Asia operations. Prior to Novotech John was Managing Director of IVF Australia and Queensland Fertility Group and sat on the Board of the parent company Virtus Health. John was previously a management consultant with the Boston Consulting Group and Partners in Performance specialising in supporting private equity transactions and implementing growth and operational improvement initiatives. John is a medical doctor by training.
CFO and Company Secretary
With a career spanning senior financial positions with a number of multinational organizations, both in North America and Australasia, Brad joined Novotech as CFO in 2006, later becoming a director in 2009. Brad began his career as a Chartered Accountant with PricewaterhouseCoopers, and has extensive experience in leading corporate finance teams across the professional services, investment banking, transportation and entertainment industries.